Sign in Subscribe
Drugs

Immunotherapy Shows Promise in Treating Metastatic Prostate Cancer

Strategic Insights

— 2 min read

Scientists in the United States have made a groundbreaking discovery in the fight against metastatic hormone-refractory prostate cancer (HRPC) using immunotherapy, a type of cancer treatment that harnesses the body's immune system to fight disease. The study, led by C.S. Higano and colleagues at the University of Washington, involved 80 men with a median age of 69 years who were treated with immunotherapy based on the GVAX platform. The researchers tested multiple dose levels of the immunotherapy, ranging from 100 x 10(6) cells to 500 x 10(6) cells, and monitored endpoints such as safety, immunogenicity, overall survival, radiologic response, and prostate-specific antigen (PSA) kinetics.

Key Takeaways:

  • The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF), a protein that stimulates the immune system to fight cancer.
  • The most common adverse effect was injection-site erythema, with 80 men treated in the study experiencing this side effect, although overall the immunotherapy was well-tolerated.
  • The median survival time was 35.0 months in the high-dose group, 20.0 months in the mid-dose group, and 23.1 months in the low-dose group, indicating that higher doses of immunotherapy may be more effective in extending overall survival.
  • PSA stabilization occurred in 15 (19%) patients, and a 50% decline in PSA was seen in 1 patient, suggesting that immunotherapy may be effective in reducing cancer progression.
  • The proportion of patients who generated an antibody response to 1 or both cell lines increased with dose, with significantly higher responses in the mid-dose and high-dose groups compared to the low-dose group.
  • Two phase 3 trials in patients with metastatic HRPC are currently underway, indicating that this promising approach to cancer treatment is being further tested in larger-scale studies.

Statistics:

  • 80 men with median age 69 years (range, 49-90 years) were treated in the study.
  • The most common adverse effect was injection-site erythema, affecting 80% of patients in the study.
  • The median survival time in the high-dose group was 35.0 months, 20.0 months in the mid-dose group, and 23.1 months in the low-dose group.
  • PSA stabilization occurred in 15 (19%) patients, with a 50% decline in PSA seen in 1 patient.
  • The proportion of patients who generated an antibody response to 1 or both cell lines increased with dose, with 10 of 23 (43%) in the low-dose group, 13 of 18 (72%) in the mid-dose group, and 16 of 18 (89%) in the high-dose group showing significant antibody responses.

Sources:

  • Higano, C.S., et al. (2009). Phase 1/2 Dose-Escalation Study of a GM-CSF-Secreting, Allogeneic, Cellular Immunotherapy for Metastatic Hormone-Refractory Prostate Cancer Editorial Comment. Journal of Urology, 181(6), 2536-2537.
  • NewsRx.com. (2009). Immunotherapy Shows Promise in Treating Metastatic Prostate Cancer. Cancer Weekly via NewsRx.com.

Read more